GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01226277
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT01225393
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01209130
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Phase 1
Completed
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01209143
A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT01207323
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Uni of Colorado Cancer Center; Anschutz Cancer Pavilion, Aurora, Colorado, United States
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT01201915
A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01196039
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT01186991
- Locations
- 🇺🇸
Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States
🇺🇸Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States
🇺🇸St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States
A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2010-08-02
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01173536
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: tocilizumabBiological: 23-Valent Pneumococcal Polysaccharide VaccineBiological: Tetanus Toxoid Adsorbed Vaccine
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2012-12-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01163747
© Copyright 2025. All Rights Reserved by MedPath